MedTrace Logo

Effect of Coffee and Agave Inulin-based Beverage on Appetite in Adults With Obesity.

NCT06527209 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-07-30

No results posted yet for this study

Summary

Nutritional treatment is key in managing obesity; however, the lack of fullness or satiety signals may affect adherence to this treatment. Coffee and inulin consumption, separately, have been shown to increase satiety and GLP-1 concentrations and reduce appetite and energy intake, but they have not been evaluated together. It is necessary to obtain scientific evidence contributing to recommendations for controlling appetite in an obesity context.

Therefore, this study aims to analyze the use of coffee and agave inulin-based beverage consumption on appetite sensations, dietary intake, and ghrelin, GLP-1, and PYY concentrations in adults with obesity.

For that purpose, a double-blind, randomized crossover clinical trial was designed to evaluate the effect of daily consumption, during two weeks, of a coffee and inulin-based beverage compared to a control beverage. Appetite sensations will be analyzed with visual analogue scales, dietary intake with a 3-day self-reporting of food intake, and appetite hormones with ELISA assays. The measurements will be performed in 6 scheduled sessions. In each session, fasting and postprandial appetite variables will be evaluated.

Conditions

Interventions

OTHER

Coffee and agave inulin-based beverage (A)

Intervention beverage: 134 mL of cold-brew coffee 18 g of agave inulin Total beverage weight: 350 g

OTHER

Control beverage (B)

Control beverage: 40 mL of cold brew coffee 5.4 g of agave inulin Total beverage weight: 350 g.

Sponsors & Collaborators

  • Hospital Civil de Guadalajara

    collaborator OTHER

  • University of Guadalajara

    lead OTHER

Principal Investigators

  • Livier N Torres, Ph.D · University of Guadalajara

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-24
Primary Completion
2025-07-31
Completion
2025-07-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06527209 on ClinicalTrials.gov